

# Clinical Oversight Review Board (CORB) Criteria for Prescribing Pegloticase (Krystexxa)

Non-Formulary **pegloticase (Krystexxa)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

**Initiation (new start) criteria:** Non-formulary **pegloticase (Krystexxa)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a Rheumatologist
- Patient has symptomatic gout with one or more of the following:
  - Three gouty flares or more in the previous 18 months
  - Presence of one or more tophi
  - Chronic gouty arthritis
- Baseline serum uric acid level greater than 8 mg/dL
- Patient has a documented contraindication, intolerance to, or failure after at least a 90-day course of therapy of allopurinol AND febuxostat (failure defined as serum uric acid level greater or equal to 6 mg/dL)

kp.org

Revised: 07/10/14  
Effective: 07/10/14

All plans offered and underwritten by  
Kaiser Foundation Health Plan of the Northwest